AR054593A1 - Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido - Google Patents
Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosidoInfo
- Publication number
- AR054593A1 AR054593A1 ARP060103274A ARP060103274A AR054593A1 AR 054593 A1 AR054593 A1 AR 054593A1 AR P060103274 A ARP060103274 A AR P060103274A AR P060103274 A ARP060103274 A AR P060103274A AR 054593 A1 AR054593 A1 AR 054593A1
- Authority
- AR
- Argentina
- Prior art keywords
- prevent
- treat
- methods
- glucosido
- pirazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente se refiere a métodos para prevenir o tratar trastornos metabolicos, para mejorar el control glucémico, para prevenir la progresion desde la tolerancia alterada a la glucosa, la resistencia a la insulina y/o desde el síndrome metabolico hasta la diabetes mellitus de tipo 2, para prevenir o tratar las complicaciones de la diabetes mellitus, para reducir el peso, para prevenir o tratar la degeneracion de las células beta pancreáticas, para tratar la hiperinsulinemia y la resistencia a la insulina y la diabetes de tipo 1, en pacientes que lo necesiten, mediante la administracion de una composicion farmacéutica que comprende un pirazol-O-glucosido como se define en la reivindicacion 1, o su profármaco, o su sal farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05016390 | 2005-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054593A1 true AR054593A1 (es) | 2007-06-27 |
Family
ID=35427576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103274A AR054593A1 (es) | 2005-07-28 | 2006-07-28 | Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido |
Country Status (18)
Country | Link |
---|---|
US (1) | US20070072813A1 (es) |
EP (1) | EP1912656A2 (es) |
JP (1) | JP2009502875A (es) |
KR (1) | KR20080043801A (es) |
CN (1) | CN101222928A (es) |
AR (1) | AR054593A1 (es) |
AU (1) | AU2006274834A1 (es) |
BR (1) | BRPI0614121A2 (es) |
CA (1) | CA2616702A1 (es) |
EA (1) | EA200800198A1 (es) |
EC (1) | ECSP088139A (es) |
IL (1) | IL188988A0 (es) |
NO (1) | NO20076346L (es) |
PE (1) | PE20070402A1 (es) |
TW (1) | TW200738246A (es) |
UY (1) | UY29694A1 (es) |
WO (1) | WO2007014895A2 (es) |
ZA (1) | ZA200710713B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7375090B2 (en) | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
EP1910391A1 (en) * | 2005-07-22 | 2008-04-16 | Boehringer Ingelheim International GmbH | Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
UY30082A1 (es) | 2006-01-11 | 2007-08-31 | Boehringer Ingelheim Int | Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
US20080020987A1 (en) * | 2006-07-20 | 2008-01-24 | Waldemar Pfrengle | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
CL2008000133A1 (es) * | 2007-01-19 | 2008-05-23 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e |
CL2008000223A1 (es) * | 2007-01-26 | 2008-05-23 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un compuesto derivado glucopiranosiloxi-pirazol; y uso para el tratamiento de uno o mas trastornos neurodegenerativos. |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
UY31290A1 (es) * | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido | |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
PE20090597A1 (es) * | 2007-08-16 | 2009-06-06 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
SG173619A1 (en) | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
WO2010127067A1 (en) * | 2009-04-30 | 2010-11-04 | Glaxosmithkline Llc | Chemical process |
EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
ES2527179T3 (es) | 2009-11-02 | 2015-01-21 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5274111A (en) * | 1992-04-07 | 1993-12-28 | American Home Products Corporation | Trifluoromethyl substituted 1H-pyrazoles and derivatives thereof |
US5264451A (en) * | 1992-04-07 | 1993-11-23 | American Home Products Corporation | Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones |
DK1213296T3 (da) * | 1999-08-31 | 2004-08-16 | Kissei Pharmaceutical | Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
DE60141156D1 (de) * | 2000-11-02 | 2010-03-11 | Ajinomoto Kk | Neue pyrazolderivate und diese enthaltende mittel gegen diabetes |
BRPI0116607B8 (pt) * | 2000-12-28 | 2021-05-25 | Kissei Pharmaceutical | derivados de glicopiranosiloxipirazol , composições farmacêuticas que os contêm e usos dos mesmos |
DE60230591D1 (de) * | 2001-02-26 | 2009-02-12 | Kissei Pharmaceutical | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung |
CA2445346C (en) * | 2001-04-27 | 2010-04-06 | Ajinomoto Co., Inc. | N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same |
EP1500403A4 (en) * | 2002-04-26 | 2008-09-17 | Ajinomoto Kk | MEANS FOR THE PREVENTION / TREATMENT OF DIABETES |
US7439232B2 (en) * | 2003-04-01 | 2008-10-21 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
DE502004008951D1 (de) * | 2003-08-26 | 2009-03-19 | Boehringer Ingelheim Pharma | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US7375090B2 (en) * | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
EP1910391A1 (en) * | 2005-07-22 | 2008-04-16 | Boehringer Ingelheim International GmbH | Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes |
-
2006
- 2006-07-24 UY UY29694A patent/UY29694A1/es not_active Application Discontinuation
- 2006-07-26 PE PE2006000904A patent/PE20070402A1/es not_active Application Discontinuation
- 2006-07-27 CN CNA2006800257283A patent/CN101222928A/zh active Pending
- 2006-07-27 TW TW095127481A patent/TW200738246A/zh unknown
- 2006-07-27 WO PCT/EP2006/064715 patent/WO2007014895A2/en active Application Filing
- 2006-07-27 AU AU2006274834A patent/AU2006274834A1/en not_active Abandoned
- 2006-07-27 EP EP06778010A patent/EP1912656A2/en not_active Withdrawn
- 2006-07-27 KR KR1020087004981A patent/KR20080043801A/ko not_active Application Discontinuation
- 2006-07-27 JP JP2008523363A patent/JP2009502875A/ja active Pending
- 2006-07-27 BR BRPI0614121-8A patent/BRPI0614121A2/pt not_active IP Right Cessation
- 2006-07-27 EA EA200800198A patent/EA200800198A1/ru unknown
- 2006-07-27 CA CA002616702A patent/CA2616702A1/en not_active Abandoned
- 2006-07-28 US US11/495,332 patent/US20070072813A1/en not_active Abandoned
- 2006-07-28 AR ARP060103274A patent/AR054593A1/es unknown
-
2007
- 2007-12-10 ZA ZA200710713A patent/ZA200710713B/xx unknown
- 2007-12-11 NO NO20076346A patent/NO20076346L/no not_active Application Discontinuation
-
2008
- 2008-01-24 IL IL188988A patent/IL188988A0/en unknown
- 2008-01-25 EC EC2008008139A patent/ECSP088139A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007014895A3 (en) | 2007-05-10 |
ECSP088139A (es) | 2008-05-30 |
TW200738246A (en) | 2007-10-16 |
CN101222928A (zh) | 2008-07-16 |
EP1912656A2 (en) | 2008-04-23 |
BRPI0614121A2 (pt) | 2011-03-09 |
IL188988A0 (en) | 2008-08-07 |
WO2007014895A2 (en) | 2007-02-08 |
AU2006274834A1 (en) | 2007-02-08 |
AU2006274834A8 (en) | 2008-07-17 |
EA200800198A1 (ru) | 2008-08-29 |
US20070072813A1 (en) | 2007-03-29 |
UY29694A1 (es) | 2007-02-28 |
KR20080043801A (ko) | 2008-05-19 |
CA2616702A1 (en) | 2007-02-08 |
NO20076346L (no) | 2008-04-23 |
JP2009502875A (ja) | 2009-01-29 |
PE20070402A1 (es) | 2007-04-30 |
ZA200710713B (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054593A1 (es) | Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido | |
CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
CL2008003153A1 (es) | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. | |
BR112013019744A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 | |
MX2007012102A (es) | Control superior de glucosa en la sangre en tratamiento de diabetes. | |
BR112013024973A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2 | |
UY31596A1 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
UY31295A1 (es) | Composicion farmacéutica que comprende un inhibidor de sglt2 | |
CL2008002227A1 (es) | Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad. | |
BRPI0718596B8 (pt) | composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina | |
AR083679A1 (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos | |
MY152037A (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | |
WO2008082602A3 (en) | Compounds and pharmaceutical compositions for the treatment of liver disorders | |
BR112016027469A2 (pt) | composição para tratamento de diabetes que compreende conjugado de análogo de insulina de ação lenta e conjugado de peptídeo insulinotrópico de ação lenta | |
AR047779A1 (es) | Composiciones y metodos para tratar diabetes | |
UY31291A1 (es) | Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido | |
CL2013000716A1 (es) | Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2. | |
MX2008004734A (es) | Composicion rica en leucina. | |
CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
BR112013029062A2 (pt) | lixisenatida e metformina para o tratamento de diabetes tipo 2 | |
MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
BR112014004726A2 (pt) | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 | |
WO2010129138A3 (en) | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment | |
AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
BR112013029269A2 (pt) | "combinação farmacêutica para uso na melhora da tolerância à glicose em pacientes com diabetes tipo 2 e o uso da mesma". |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |